drugset / Trial / NCT00568464

Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)

NCT00568464

Phase 2 Terminated 10 enrolled Fudan University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical trial was to evaluate the efficacy and tolerability of the sequential therapy of VCD/IE in the patients with ESFT.

Timeline

Start
2007-03
Primary completion
2009-05
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject ADM Unknown 75 mg/m2
Subject CTX Unknown 1200 mg/m2
Subject Etoposide Small molecule 100 mg/m2
Subject IFO Unknown 1800 mg/m2
Subject VCR Unknown 2 mg
Background 2-MERCAPTOETHANESULFONIC ACID Small molecule 240 mg/m2
Background 2-MERCAPTOETHANESULFONIC ACID Small molecule 360 mg/m2
Background G-CSF Unknown 300 ug

Indications